Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Related Posts
Mackow NA, Shao W, Ge L, Komarow L, Jiang J, Boutzoukas A, Chen L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade[...]
Rhee CM, Zisman-Ilani Y, Kalantar-Zadeh K, Nguyen DV. Continuous glucose monitoring in patients with chronic kidney disease on dialysis and with kidney transplantation. Curr Opin[...]
Lobo AS, Vaughan L, Ainsworth AJ, Felt M, Elali I, Arriola-Montenegro J, Garovic VD, Kattah AG. Sex hormones and sexual health in chronic kidney disease[...]